Dr James Hamilton (Vice President Clinical Development at Arrowhead Pharmaceuticals) discusses RNA Interference Targeting Apolipoprotein C-III (APOC3) Results in Deep and Prolonged Reductions in Plasma Triglycerides at AHA 2019.

Filmed on site at AHA 2019 by Radcliffe Cardiology.

Videography: Tom Green